Detalles de la búsqueda
1.
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.
Cytotherapy
; 25(7): 763-772, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37055320
2.
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Med
; 5(1): 42-61.e23, 2024 Jan 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38181791
3.
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.
bioRxiv
; 2023 Jan 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36711580
4.
Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET.
Expert Opin Biol Ther
; 23(11): 1137-1149, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38078403
5.
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.
J Med Chem
; 66(16): 11040-11055, 2023 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37561993
6.
Antibody-based binding domain fused to TCRγ chain facilitates T cell cytotoxicity for potent anti-tumor response.
Oncogenesis
; 12(1): 33, 2023 Jun 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37349298
7.
A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells.
Front Oncol
; 12: 884196, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35664753
8.
Delivering an mRNA vaccine using a lymphatic drug delivery device improves humoral and cellular immunity against SARS-CoV-2.
J Mol Cell Biol
; 14(6)2022 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35803578
9.
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
Eur J Med Chem
; 240: 114570, 2022 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35779291
10.
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
Eur J Med Chem
; 240: 114596, 2022 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35839690
11.
Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay.
ACS Cent Sci
; 8(2): 192-204, 2022 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35229034
12.
Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants.
Mol Ther Nucleic Acids
; 30: 465-476, 2022 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36345542
13.
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.
Sci Rep
; 12(1): 15517, 2022 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36109550
14.
Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
Med
; 3(10): 705-721.e11, 2022 10 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36044897
15.
Salicylanilides Reduce SARS-CoV-2 Replication and Suppress Induction of Inflammatory Cytokines in a Rodent Model.
ACS Infect Dis
; 7(8): 2229-2237, 2021 08 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34339171
16.
The P3 O - Tert -Butyl-Threonine is Key to High Cellular and Antiviral Potency for Aldehyde-Based SARS-CoV-2 Main Protease Inhibitors.
bioRxiv
; 2021 Dec 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34981047
17.
The N -Terminal Carbamate is Key to High Cellular and Antiviral Potency for Boceprevir-Based SARS-CoV-2 Main Protease Inhibitors.
bioRxiv
; 2021 Dec 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34981058
18.
The role of afferent pulmonary innervation in ARDS associated with COVID-19 and potential use of resiniferatoxin to improve prognosis: A review.
Med Drug Discov
; 5: 100033, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32292906
19.
Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.
Med Drug Discov
; 5: 100026, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32289117
20.
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Med
; 5(2): 169-171, 2024 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38340710